TY - JOUR
T1 - High-echoic line tracing of transthoracic echocardiography accurately assesses right ventricular enlargement in adult patients with atrial septal defect
AU - Sato, Tasuku
AU - Sakamoto, Ichiro
AU - Ken-Ichi, Hiasa
AU - Kawakubo, Masateru
AU - Ishikita, Ayako
AU - Umemoto, Shintaro
AU - Kang, Min Jeong
AU - Sawatari, Hiroyuki
AU - Chishaki, Akiko
AU - Shigeto, Hiroshi
AU - Tsutsui, Hiroyuki
N1 - Funding Information:
This study was supported by a “medical stuff research grant” from the Japanese Circulation Society. We acknowledge the support of the staff of the Heart Center of Kyushu University Hospital (Fukuoka, Japan), especially to Goro Kawahara, Tokiko Koya, Asami Hanada, Yuya Fukudome, Ryoko Hayashi, Miki Kawamura, Manami Ito, and Takuto Moriyama, who acquired the TTE images and data. We would like to thank Editage ( www.editage.com ) for English language editing.
Funding Information:
Tasuku Sato, Ichiro Sakamoto, Masateru Kawakubo, Ayako Ishikita, Shintaro Umemoto, Min-Jeong Kang, Hiroyuki Sawatari, Akiko Chishaki, and Hiroshi Shigeto, declare that there are no conflicts of interest. Ken-ichi Hiasa received remuneration from Daiichi Sankyo, Nippon Boehringer Ingelheim, Pfizer, Bristol-Myers Squibb, Bayer, and Otsuka Pharmaceutical. Hiroyuki Tsutusi received remuneration from Kowa, Teijin Pharma, Nippon Boehringer, Ingelheim, Mitsubishi Tanabe Pharma, Pfizer Japan, Ono Pharmaceutical, Daiichi Sankyo, Novartis Pharma, Bayer Yakuhin, Otsuka Pharmaceutical, and AstraZeneca; manuscript fees from Nippon Rinsho; research funding from Abbott Medical Japan, Otsuka Pharmaceutical, Boston Scientific Japan, Ono Pharmaceutical, Bayer Yakuhin, Nippon Boehringer Ingelheim, St.Mary’s Hospital, Teijin Pharma, Daiichi Sankyo, and Mitsubishi Tanabe Pharma; and donations Abbott Medical Japan, Otsuka Pharmaceutical, Boston Scientific Japan, Ono Pharmaceutical, Bayer Yakuhin, Nippon Boehringer Ingelheim, St.Mary's Hospital, Teijin Pharma, Daiichi Sankyo, and Mitsubishi Tanabe Pharma. Hiroyuki Tsutsui is a member of Circulation Journal’s editorial team.
Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer Nature B.V.
PY - 2022
Y1 - 2022
N2 - Accurate measurement of right ventricular (RV) size using transthoracic echocardiography (TTE) is important for evaluating the severity of congenital heart diseases. The RV end-diastolic area index (RVEDAi) determined using TTE is used to assess RV dilatation; however, the tracing line of the RVEDAi has not been clearly defined by the guidelines. This study aimed to determine the exact tracing method for RVEDAi using TTE. We retrospectively studied 107 patients with atrial septal defects who underwent cardiac magnetic resonance imaging (CMR) and TTE. We measured the RVEDAi according to isoechoic and high-echoic lines, and compared it with the RVEDAi measured using CMR. The isoechoic line was defined as the isoechoic endocardial border of the RV free wall, whereas the high-echoic line was defined as the high-echoic endocardial border of the RV free wall more outside than the isoechoic line. RVEDAi measured using high-echoic line (high-RVEDAi) was more accurately related to RVEDAi measured using CMR than that measured using isoechoic line (iso-RVEDAi). The difference in the high-RVEDAi was 0.3 cm2/m2, and the limit of agreement (LOA) was − 3.7 to 4.3 cm2/m2. With regard to inter-observer variability, high-RVEDAi was superior to iso-RVEDAi. High-RVEDAi had greater agreement with CMR-RVEDAi than with iso-RVEDAi. High-RVEDAi can become the standard measurement of RV size using two-dimensional TTE.
AB - Accurate measurement of right ventricular (RV) size using transthoracic echocardiography (TTE) is important for evaluating the severity of congenital heart diseases. The RV end-diastolic area index (RVEDAi) determined using TTE is used to assess RV dilatation; however, the tracing line of the RVEDAi has not been clearly defined by the guidelines. This study aimed to determine the exact tracing method for RVEDAi using TTE. We retrospectively studied 107 patients with atrial septal defects who underwent cardiac magnetic resonance imaging (CMR) and TTE. We measured the RVEDAi according to isoechoic and high-echoic lines, and compared it with the RVEDAi measured using CMR. The isoechoic line was defined as the isoechoic endocardial border of the RV free wall, whereas the high-echoic line was defined as the high-echoic endocardial border of the RV free wall more outside than the isoechoic line. RVEDAi measured using high-echoic line (high-RVEDAi) was more accurately related to RVEDAi measured using CMR than that measured using isoechoic line (iso-RVEDAi). The difference in the high-RVEDAi was 0.3 cm2/m2, and the limit of agreement (LOA) was − 3.7 to 4.3 cm2/m2. With regard to inter-observer variability, high-RVEDAi was superior to iso-RVEDAi. High-RVEDAi had greater agreement with CMR-RVEDAi than with iso-RVEDAi. High-RVEDAi can become the standard measurement of RV size using two-dimensional TTE.
UR - http://www.scopus.com/inward/record.url?scp=85136633049&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85136633049&partnerID=8YFLogxK
U2 - 10.1007/s10554-022-02712-x
DO - 10.1007/s10554-022-02712-x
M3 - Article
C2 - 36598698
AN - SCOPUS:85136633049
SN - 1569-5794
JO - International Journal of Cardiovascular Imaging
JF - International Journal of Cardiovascular Imaging
ER -